Breaking News Instant updates and real-time market news.

TSS

TSYS

$113.42

13.81 (13.86%)

, GPN

Global Payments

$153.42

5.45 (3.68%)

09:15
05/28/19
05/28
09:15
05/28/19
09:15

Fly Intel: Pre-market Movers

HIGHER: TSYS (TSS), up 5% after announcing a definitive agreement to combine in an all-stock merger of equals with Global Payments (GPN)... TransEnterix (TRXC), up 9% after receiving Japanese regulatory approval for the Senhance Surgical System... Jumei (JMEI), up 12% after announcing a $100M share repurchase plan. UP AFTER EARNINGS: Anaplan (PLAN), up 11%... Jianpu Technology (JT), up 3%... Momo (MOMO), up 7%. LOWER: Global Payments (GPN), down 3% after announcing merger of equals deal with TSYS... BioMarin (BMRN), down 4% after an update to its previously reported results of an open-label Phase 1/2 study and also reporting results of a Phase 3 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A... Nutanix (NTNX), down 4% after Morgan Stanley analyst Katy Huberty downgraded the stock to Equal Weight from Overweight... Booz Allen (BAH), down 1% after earnings.

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

BMRN

BioMarin

$89.06

2.1 (2.41%)

TRXC

TransEnterix

$1.26

0.055 (4.58%)

JMEI

Jumei

$2.31

0.05 (2.21%)

PLAN

Anaplan

$37.12

-0.94 (-2.47%)

JT

Jianpu Technology

$4.76

0.045 (0.95%)

MOMO

Momo

$26.02

-0.64 (-2.40%)

BAH

Booz Allen

$62.36

0.44 (0.71%)

NTNX

Nutanix

$35.15

0.45 (1.30%)

  • 28

    May

  • 28

    May

  • 28

    May

  • 28

    May

  • 28

    May

  • 30

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 09

    Jul

  • 13

    Nov

TSS TSYS
$113.42

13.81 (13.86%)

05/24/19
SPHN
05/24/19
NO CHANGE
SPHN
Global Payments, TSYS tie-up would likely be highly accretive, says Stephens
Stephens analyst Brett Huff noted that Bloomberg reports that Global Payments (GPN) and TSYS (TSS) have held talks about a potential merger, joint venture and/or partnerships. While he has previously thought that Global Payments had the luxury of "waiting and seeing" if combining consumer funding account with a merchant POS experience, such as the Fiserv (FISV)-First Data (FDC) and FIS (FIS)-Worldpay (WP) deals will do, would yield enough strategic value, he suspects a sooner deal might be driven by the companies' desire to not just achieve larger scale but also achieve that scale with high-quality assets. Huff said he thinks any deal would likely be highly accretive given overlaps and both companies' track record for realizing cost synergies and he also sees limited antitrust concern. Huff also thinks a Global Payments-TSYS combination would increase the chances that assets such as ACI Worldwide (ACIW), Bottomline Technologies (EPAY), Jack Henry (JKHY), USA Technologies (USAT) and Q2 Holdings (QTWO) would likely be bought.
05/24/19
RHCO
05/24/19
NO CHANGE
Target $175
RHCO
Buy
Global Payments / TSYS combination makes strategic sense, says SunTrust
SunTrust analyst Andrew Jeffrey keeps his Buy rating and $175 price target on Global Payments (GPN) after last night's Bloomberg report that the company is considering a possible merger of a joint venture arrangement with Total Systems (TSS). The analyst contends that the combination makes strategic sense in the "consolidating Payments industry" and would result in significant cost synergies. Jeffrey notes that Global Payments is his favorite merchant processor given its "leading global solutions, vertical software, and strong incremental margin", adding he would buying "aggressively" on this news.
04/24/19
KEYB
04/24/19
NO CHANGE
Target $106
KEYB
Overweight
TSYS price target raised to $106 from $95 at KeyBanc
KeyBanc analyst Josh Beck raised his price target for TSYS to $106 from $95 following quarterly results. The analyst believes budding initiatives like a broader mPOS push, consumer innovation, and issuer pipeline could translate into upside. He reiterates an Overweight rating on the shares and sees an attractive valuation relative to peers.
04/24/19
SPHN
04/24/19
NO CHANGE
Target $108
SPHN
Overweight
TSYS pullback on earnings a buying opportunity, says Stephens
Stephens analyst Brett Huff said he was surprised by the revenue miss reported by TSYS (TSS) given generally strong trends year-to-date, but he views any post-earnings pullback as a buying opportunity as he thinks the headwinds that impacted the quarter are temporary. Additionally, he still considers TSYS the "least expensive high-quality payment asset" and believes that "at some point" FIS/Worldpay will be a suitor. He reiterates an Overweight rating on TSYS shares and raised his price target on the stock to $108 from $104.
GPN Global Payments
$153.42

5.45 (3.68%)

05/10/19
NOMU
05/10/19
NO CHANGE
Target $105
NOMU
Neutral
Global Payments price target raised to $105 from $94 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for Global Payments to $105 from $94 following the company's Q1 results but keeps a Reduce rating on the shares. At face value, Global Payments' organic growth in North America accelerated, Dolev tells investors in a research note. However, the analyst says he's at odds with the "puzzling discrepancy between dull network fees growth (+3%) and faster core sales growth (+9%)."
05/07/19
SUSQ
05/07/19
UPGRADE
SUSQ
Positive
Global Payments upgraded to Positive from Neutral at Susquehanna
BMRN BioMarin
$89.06

2.1 (2.41%)

05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/22/19
JPMS
05/22/19
NO CHANGE
Target $133
JPMS
Overweight
JPMorgan likes BioMarin risk/reward into gene therapy update
JPMorgan analyst Cory Kasimov likes the risk/reward on shares of BioMarin Pharmaceuticals into the three-year update for the company's valrox gene therapy program in hemophilia A, which is expected by June 7. The analyst expects valrox "to continue to look like an approvable and commercially relevant product." However, it can also be argued that BioMarin is undervalued at these levels even without valrox, Kasimov tells investors in a research note. Following a sum-of-the-parts analysis, the analyst believes BioMarin "represents a compelling opportunity at this time." He keeps an Overweight rating on the shares with a $133 price target.
05/28/19
MSCO
05/28/19
NO CHANGE
Target $120
MSCO
Overweight
BioMarin shares should be 'up significantly' on Valrox data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said BioMarin's 3-year data update reported by BioMarin this morning support the slowing of factor level declines with Valrox. The separately reported Phase 3 data support an accelerated filing for valoctocogene roxaparvovec for adults with severe hemophilia A, added Harrison, who thinks the stock should be "up significantly" following the "upside surprise" that today's reports represent. The analyst, who expects BioMarin to trade to "at least $100+" following the news, has an Overweight rating and $120 price target on the stock.
05/28/19
PIPR
05/28/19
NO CHANGE
Target $120
PIPR
Overweight
BioMarin initial selloff on valrox data 'wholly misplaced,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using this morning's weakness in shares of BioMarin as a buying opportunity. The stock in premarket trading is now little changed after selling off earlier in the morning. The initial premarket reaction to year three Phase 1/2 data and initial Phase 3 data for valrox is "wholly misplaced," Raymond tells investors in a research note. Specifically, with mean F8 levels going from 36.4 IU/dL at year two to 32.7 IU/dL at year three, and median going from 26.2 IU/dL to 19.9 IU/dL, the bear scenario 10-15 IU/dL is "off the table," says the analyst. He believes that while some investors "appear to be nitpicking" management's characterization of a plateau, the plateau is "exactly what we have here." Raymond expects BioMarin shares to recover this morning's conference call and he keeps an Overweight rating on the name with a $120 price target.
TRXC TransEnterix
$1.26

0.055 (4.58%)

05/22/19
05/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. RA Pharmaceuticals (RARX) initiated with an Outperform at SVB Leerink. 2. Horace Mann (HMN) initiated with a Buy at Sandler O'Neill. 3. Titan Medical (TMDI) initiated with an Overweight at Piper Jaffray while TransEnterix (TRXC) was initiated with a Neutral. 4. Red River Bancshares (RRBI) initiated with an Outperform at Fig Partners. 5. Semtech (SMTC) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
BTIG
05/14/19
UPGRADE
Target $3
BTIG
Buy
TransEnterix upgraded to Buy from Neutral at BTIG
BTIG analyst Sean Lavin upgraded TransEnterix (TRXC) to Buy from Neutral with a $3 price target. The 40% pullback in the shares following the Q1 miss is overdone, Lavin tells investors in a research note. Individual issues at certain hospitals drove the shortfall, and there is a chance that next quarter and beyond could be better, says the analyst. He believes that while Intuitive Surgical (ISRG) using leasing to gain customers adds to TransEnterix's near-term risk, the shares offer more upside potential than downside risk at current prices.
05/22/19
PIPR
05/22/19
INITIATION
Target $1.6
PIPR
Neutral
TransEnterix initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst JP McKim started TransEnterix with a Neutral rating and $1.60 price target. The analyst is bullish on the growth prospects of robotic surgery but wants to see better uptake and physician feedback on the company's Senhance surgical robotic system before becoming more constructive on the shares.
11/09/18
LTCO
11/09/18
UPGRADE
Target $4.5
LTCO
Buy
TransEnterix upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen upgraded TransEnterix to Buy while lowering his price target for the shares to $4.50 from $6.
JMEI Jumei
$2.31

0.05 (2.21%)

PLAN Anaplan
$37.12

-0.94 (-2.47%)

02/26/19
RHCO
02/26/19
NO CHANGE
Target $42
RHCO
Buy
Anaplan price target raised to $42 from $28 at SunTrust
SunTrust analyst Terry Tillman raised his price target on Anaplan to $42 and kept his Buy rating after its "strong" Q4 results that were highlighted by a 49% growth in revenue and a 54% growth in billings - double the consensus. The analyst also cites the management's comments on the quarter, including its "highest net new ACV, highest overall customer adds and the highest G2K customer adds." Tillman adds that the recent buyout of Anaplan's smaller competitor give the stock further upside potential on top of the management's recent investment efforts in growing sales and products.
02/26/19
NEED
02/26/19
NO CHANGE
Target $42
NEED
Buy
Anaplan price target raised to $42 from $38 at Needham
Needham analyst Scott Berg raised his price target on Anaplan to $42 and kept his Buy rating after its "impressive" Q4 results that featured a 54% billings growth, which suggests that the company's "accelerated investments are ramping productivity." The analyst believes that 2019 will be an "investment year" for Anaplan as it builds its global partner network with expanded sales offices domestically and internationally. Given the company's strong billings however, Berg also contends that the management is being conservative with its FY20 guidance.
03/25/19
MONN
03/25/19
INITIATION
Target $50
MONN
Buy
Anaplan initiated with a Buy at Monness Crespi
Monness Crespi analyst Brian White initiated Anaplan with a Buy and $50 price target saying it is an emerging SaaS vendor pioneering the Connected Planning category.
04/11/19
FBNS
04/11/19
INITIATION
Target $45
FBNS
Outperform
Anaplan initiated with an Outperform at FBN Securities
FBN Securities started Anaplan with an Outperform rating and $45 price target.
JT Jianpu Technology
$4.76

0.045 (0.95%)

03/01/19
JPMS
03/01/19
UPGRADE
Target $9.5
JPMS
Overweight
Jianpu Technology upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alex Yao upgraded Jianpu Technology to Overweight and raised his price target for the shares to $9.50 from $5.50. The analyst sees an improving operating environment and stronger earnings growth following the company's Q4 results.
MOMO Momo
$26.02

-0.64 (-2.40%)

12/07/18
SBSH
12/07/18
DOWNGRADE
SBSH
Neutral
Momo downgraded to Neutral from Buy at Citi
12/07/18
12/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Secureworks (SCWX) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Outperform at First Analysis. 2. Methanex (MEOH) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying he is now more cautious on the Chemicals space and he expects recession risk signals to continue emerging over the next few quarters. 3. Expeditors (EXPD) downgraded to Sell from Neutral at Goldman Sachs with analyst Matthew Reustle saying he sees "headwinds on the horizon" amid continued deceleration in the company's airfreight business and structural headwinds in its ocean freight business. 4. Chesapeake (CHK) downgraded to Underweight from Neutral at JPMorgan while Devon Energy (DVN) was downgraded to Neutral from Overweight. 5. Momo (MOMO) downgraded to Equal Weight from Overweight at Morgan Stanley and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
NOMU
03/13/19
NO CHANGE
Target $47
NOMU
Buy
Momo price target raised to $47 from $41 at Nomura Instinet
Nomura Instinet analyst Jialong Shi raised his price target for Momo to $47 from $41 following the company's "solid beat" in Q4. The market would be encouraged to see that Momo's revenue sources are becoming more diversified, Shi tells investors in a research note. He keeps a Buy rating on the shares.
03/13/19
MSCO
03/13/19
UPGRADE
MSCO
Overweight
Momo upgraded to Overweight from Equal Weight at Morgan Stanley
BAH Booz Allen
$62.36

0.44 (0.71%)

05/09/19
05/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Booz Allen (BAH) initiated with a Buy at Goldman Sachs. 2. CACI (CACI) initiated with a Buy at Goldman Sachs. 3. SAIC (SAIC) initiated with a Neutral at Goldman Sachs 4. Avista (AVA) initiated with an Underperform at BofA/Merrill. 5. Restaurant Brands (QSR) initiated with a Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/19
GSCO
05/09/19
INITIATION
Target $72
GSCO
Buy
Booz Allen initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Gavin Parsons started Booz Allen Hamilton with a Buy rating and $72 price target. The analyst sees Booz Allen as growing the fastest organically in the group over the near to medium term given its positioning in key budget growth areas. The analyst initiated coverage of US Government IT & Services with a favorable outlook on the sector. He believes we are in the "sweet-spot" of a Defense budget upturn and expects the sector to outperform the market, with "multiple years" of growth ahead.
01/04/19
WELS
01/04/19
NO CHANGE
Target $30
WELS
Outperform
Wells Fargo favors Perspecta, Booz Allen, CACI in government services
In a research note on government services companies, Wells Fargo analyst Ed Caso tells investors that he continues to favor Booz Allen Hamilton (BAH), CACI International (CACI), Leidos (LDOS), Perspecta (PRSP) and ManTech (MANT) as the government continues its shutdown, though he says near-term outperfomance may be difficult despite being "defensive" names. Caso notes that this shutdown is different than the 16-day shutdown in October 2013, as this time about 75% of the government is funded, particularly Defense/Intel versus none in 2013. Though services providers fell into the 2013 shutdown, then recovered starting mid-event, this time, investor concern has weighed on the group for a few months now, which he believes has dampened the group's traditional defensive characteristics.
11/05/18
11/05/18
DOWNGRADE

Underperform
Booz Allen downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Ronald Epstein downgraded Booz Allen to Underperform from Neutral but raised estimates and his price target to $50 from $47. Epstein believes Booz Allen is approaching fair value at current levels and the tight labor market and challenges in hiring will put a constraint on growth. Further, the analyst views the Department of Justice civil and criminal investigation as an overhang.
NTNX Nutanix
$35.15

0.45 (1.30%)

05/16/19
OTRG
05/16/19
INITIATION
OTRG
Mixed
Nutanix initiated with a Mixed at OTR Global
OTR Global initiated Nutanix with a Mixed rating citing Dell partnership uncertainty, somewhat weakening win rates, and difficult forcasting.
05/09/19
ODEN
05/09/19
INITIATION
ODEN
Buy
Nutanix initiated with a Buy at Odeon Capital
05/28/19
MSCO
05/28/19
DOWNGRADE
MSCO
Equal Weight
Nutanix downgraded to Equal Weight from Overweight at Morgan Stanley
05/28/19
MSCO
05/28/19
DOWNGRADE
Target $37
MSCO
Equal Weight
Morgan Stanley downgrades Nutanix to Equal Weight, sees slower turnaround
As previously reported, Morgan Stanley analyst Katy Huberty downgraded Nutanix (NTNX) to Equal Weight from Overweight, contending that the combination of slowing industry demand and competition from Dell (DELL) will slow down a full recovery in its business. She has lowered her 2019 revenue estimate to $1.414B from $1.47B to reflect normal July quarter seasonality, versus her prior forecast for a faster recovery. She also now forecast revenue growth below consensus through FY20, noted Huberty, who lowered her price target on Nutanix shares to $37 from $53.

TODAY'S FREE FLY STORIES

GRUB

GrubHub

$61.36

-2.42 (-3.79%)

12:55
09/19/19
09/19
12:55
09/19/19
12:55
Options
GrubHub put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/19/19
09/19
12:55
09/19/19
12:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

XGN

Exagen

$0.00

(0.00%)

12:54
09/19/19
09/19
12:54
09/19/19
12:54
Syndicate
Breaking Syndicate news story on Exagen »

Exagen opens at $16.80,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

12:50
09/19/19
09/19
12:50
09/19/19
12:50
Syndicate
Breaking Syndicate news story on Exagen »

Exagen indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CAIXY

CaixaBank

$0.00

(0.00%)

12:46
09/19/19
09/19
12:46
09/19/19
12:46
Periodicals
France's CNP, CaixaBank near $1.7B insurance pact, Reuters reports »

France's CNP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$19.00

0.06 (0.32%)

12:45
09/19/19
09/19
12:45
09/19/19
12:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$62.58

-1.2 (-1.88%)

, UBER

Uber

$34.10

-0.14 (-0.41%)

12:43
09/19/19
09/19
12:43
09/19/19
12:43
Hot Stocks
GrubHub sinks after Jim Chanos announces short position »

Shares of GrubHub (GRUB)…

GRUB

GrubHub

$62.58

-1.2 (-1.88%)

UBER

Uber

$34.10

-0.14 (-0.41%)

DVA

DaVita

$59.91

-1.39 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MACK

Merrimack

$5.32

-0.04 (-0.75%)

12:38
09/19/19
09/19
12:38
09/19/19
12:38
Hot Stocks
Western Standard discloses 6.3% stake in Merrimack Pharmaceuticals »

Eric Andersen's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PLAN

Anaplan

$50.67

-0.13 (-0.26%)

12:35
09/19/19
09/19
12:35
09/19/19
12:35
Options
Anaplan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

HWBK

Hawthorn Bancshares

$23.20

0.01 (0.04%)

12:34
09/19/19
09/19
12:34
09/19/19
12:34
Hot Stocks
Hawthorn Bancshares authorizes $5M for common stock repurchase program »

Hawthorn Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$63.75

-0.03 (-0.05%)

, UBER

Uber

$34.26

0.02 (0.06%)

12:33
09/19/19
09/19
12:33
09/19/19
12:33
Hot Stocks
Chanos not positive on any company with food delivery business »

Jim Chanos, founder of…

GRUB

GrubHub

$63.75

-0.03 (-0.05%)

UBER

Uber

$34.26

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$71.88

0.3 (0.42%)

, MO

Altria Group

$40.22

-0.62 (-1.52%)

12:33
09/19/19
09/19
12:33
09/19/19
12:33
Hot Stocks
CDC says vaping illnesses increase to 530 probable cases »

The CDC said in a…

PM

Philip Morris

$71.88

0.3 (0.42%)

MO

Altria Group

$40.22

-0.62 (-1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$63.79

0.01 (0.02%)

12:31
09/19/19
09/19
12:31
09/19/19
12:31
Hot Stocks
Chanos says GrubHub drivers outside major cities making $6-$7 per hour »

Jim Chanos, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$63.82

0.04 (0.06%)

12:30
09/19/19
09/19
12:30
09/19/19
12:30
Hot Stocks
Chanos says GrubHub making 'almost no money' per order »

Jim Chanos, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
09/19/19
09/19
12:30
09/19/19
12:30
General news
Today's U.S. reports »

Today's U.S. reports…

GRUB

GrubHub

$63.82

0.04 (0.06%)

12:29
09/19/19
09/19
12:29
09/19/19
12:29
Hot Stocks
Chanos says GrubHub take-rates coming down »

Jim Chanos, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$63.80

0.02 (0.03%)

12:28
09/19/19
09/19
12:28
09/19/19
12:28
Hot Stocks
Chanos announces short position in GrubHub »

Jim Chanos, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLBD

Real Brands

$0.00

(0.00%)

, APHA

Aphria

$6.18

-0.1 (-1.59%)

12:27
09/19/19
09/19
12:27
09/19/19
12:27
On The Fly
Rising High: An exclusive talk with CBD brand-building company Real Brands »

In this edition of…

RLBD

Real Brands

$0.00

(0.00%)

APHA

Aphria

$6.18

-0.1 (-1.59%)

ACB

Aurora Cannabis

$5.19

-0.075 (-1.42%)

CVSI

CV Sciences

$0.00

(0.00%)

CTST

CannTrust

$1.41

0.14 (11.02%)

CGC

Canopy Growth

$27.22

-1.6 (-5.55%)

CRON

Cronos Group

$10.50

-0.455 (-4.15%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.15

0.075 (7.01%)

TLRY

Tilray

$29.90

-0.605 (-1.98%)

ZYNE

Zynerba

$7.94

-0.9 (-10.18%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 02

    Oct

FDX

FedEx

$150.64

-0.27 (-0.18%)

12:27
09/19/19
09/19
12:27
09/19/19
12:27
Upgrade
FedEx rating change  »

FedEx upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

DVA

DaVita

$60.86

-0.44 (-0.72%)

12:26
09/19/19
09/19
12:26
09/19/19
12:26
Hot Stocks
Chanos says DaVita has had no earnings growth since 2010 despite buybacks »

Jim Chanos, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$42.99

-0.24 (-0.56%)

12:26
09/19/19
09/19
12:26
09/19/19
12:26
Hot Stocks
Twitter's Head of Global Public Policy Colin Crowell to leave the company »

Colin Crowell, a VP at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

DVA

DaVita

$60.86

-0.44 (-0.72%)

, BRK.A

Berkshire Hathaway

$316,270.26

-180 (-0.06%)

12:25
09/19/19
09/19
12:25
09/19/19
12:25
Hot Stocks
Chanos says 'bad look' for insurer like Berkshire Hathaway to own DaVita »

Jim Chanos, founder of…

DVA

DaVita

$60.86

-0.44 (-0.72%)

BRK.A

Berkshire Hathaway

$316,270.26

-180 (-0.06%)

BRK.B

Berkshire Hathaway

$210.64

-0.22 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PODD

Insulet

$151.33

3.29 (2.22%)

12:25
09/19/19
09/19
12:25
09/19/19
12:25
Conference/Events
Insulet participates in a conference call with SVB Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

A

Agilent

$77.92

0.35 (0.45%)

12:25
09/19/19
09/19
12:25
09/19/19
12:25
Conference/Events
Agilent participates in a conference call with Cowen »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 01

    Oct

WRK

WestRock

$36.38

-0.41 (-1.11%)

12:23
09/19/19
09/19
12:23
09/19/19
12:23
Hot Stocks
WestRock sees pre-tax impact from Hurricane Dorian of approx. $9M »

WestRock Company provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.